Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance

To evaluate the single-dose pharmacokinetic (PK) profiles of ceftaroline and avibactam following intravenous (IV) administration of ceftaroline fosamil/avibactam ("CXL") in adults with augmented renal clearance (ARC).

Inclusion criteria

• Male or female adults ≥ 18 and ≤ 55 years old
• Augmented renal clearance, defined as:

• Estimated CrCl ≥ 115 mL/min (calculated using modified Cockcroft-Gault, before the measured 8-hour urine collection)
• Measured CrCl ≥ 140 mL/min (from an 8-hour urine collection)
• Hospitalized and diagnosed with SIRS, defined by at least 2 of the following:

• Temperature (oral, rectal, tympanic, or core) > 38.5°C or < 35.0°C
• Heart rate > 90 beats/min
• Respiratory rate > 20 breaths/min or PaCO2 < 32 mmHg
• Leukocytosis (> 12,000 white blood cells [WBC]/mm3), leukopenia (< 4000 WBC/mm3), or bandemia (> 10% immature neutrophils [bands] regardless of total peripheral WBC)
• Requires indwelling urinary bladder catheter per standard of care (through the end of the 8-hour urine collection)

Exclusion criteria

• History of any known hypersensitivity or allergic reaction to cephalosporins or any β-lactam antimicrobial (eg, penicillins)
• History of chronic kidney disease, hemodialysis, or peritoneal dialysis; or history of acute renal replacement therapy (eg, hemodialysis, hemofiltration) associated with current illness
• Suspected rhabdomyolysis or creatine kinase > 10,000 U/L
• Significant anemia defined as hemoglobin < 9 g/dL or hematocrit < 27%
• Transfusion of packed red blood cells (PRBC) or whole blood within 24 hours of study drug infusion or anticipated need for a transfusion before the last PK blood sample is collected
• If female, currently pregnant or breastfeeding